Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 17.5 mg/5 mL) |
| Drug Class | GD2-binding monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Summary
- Dinutuximab (Unituxin) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
- Two systematic reviews/meta-analyses were reviewed which provided information on dinutuximab's efficacy and safety profile in treating high-risk neuroblastoma.
- The immunotherapy approach using dinutuximab has been identified as an effective therapy for pediatric cancers, particularly those presenting unique adverse events different from traditional chemotherapy according to one review.
- Nurses are recommended to familiarize themselves with the unique adverse event profiles associated with individual immunotherapy agents like dinutuximab due its rapidly emerging role in treating pediatric cancers.
- A randomized controlled trial included within a meta-analysis showed that overall survival rates favored the group receiving dinutixumab-containing immunotherapy compared to standard therapy after autologous haematopoietic stem cell transplantation(HSCT).
- Despite promising results regarding overall survival and event-free survival rates favoring dinutixumab-containing immunotherapy over standard treatments post-HSCT, more research is needed due to lack of data on adverse events related specifically to this drug regimen according another review analyzed here.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Unituxin (dinutuximab) Prescribing Information. | 2020 | FDA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Clinical and pharmacoeconomic combined report: dinutuximab (Unituxin) for neuroblastoma. | 2021 | CADTH |
| Commonly reported adverse events associated with pediatric immunotherapy: a systematic review from the Children’s Oncology Group. | 2021 | Journal of Pediatric Oncology Nursing |
| Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. | 2019 | Cochrane Database of Systematic Reviews |
| Final clinical guidance report: dinutuximab (Unituxin) for neuroblastoma. | 2019 | CADTH |